Anyway, aren’t the “Me-too” drugs and devices critical to competition?
What we need is a “health-care Fed”: A panel of independent experts, consumers and ethicists who would make these tough decisions based on scientific evidence about what works, and what doesn’t.
Technologies that are real advances would go on the “A list” and be covered in full. “Me-too” drugs or devices with modest benefit for patients would only get partial coverage. And forget about treatments with unsubstantiated efficacy.
Making them more expensive (to the paying party) than the first movers defeats the purpose of competition.